VC: Ception lands $63M in third round



Ception lands $63M in third round

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Ception Therapeutics
Malvern Hill, PA

$63M
Third

Essex Woodlands Health Ventures

Much of that money will be used to advance a late-stage biologic compound in clinical development for multiple inflammatory conditions, a small molecule anti-TNF program and other discovery programs.

Proacta
San Diego

$35M
Second

Clarus Ventures

Much of that money will be used to develop PR-104, a compound that is designed to kill cancer cells.

Avesthagen
India

$32.5M
Third

Fidelity International

The money will go to R&D, infrastructure and the acquisition of technology companies.

ActoGeniX
Belgium

$25.9M
First

GIMV and Life Sciences Partners

ActoGeniX is developing a pipeline of therapeutic products based on its TopActTM technology platform.

Xcellerex
Marlborough, MA

$11M
Second

SCG Group and Kleiner Perkins Caufield and Byers

Xcellerex is commercializing a new manufacturing program that uses disposable components to produce multiple products.

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.